-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5

Benzinga·09/22/2026 16:40:02
Diffusion vocale
Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.